BioSymetrics (a Lunai Bioworks company)

BioSymetrics, a Lunai Bioworks company, is positioned at the forefront of innovation in the drug discovery sector. Founded in 2015 and headquartered in the United States, this phenomics-driven firm leverages its proprietary patent-pending technology, Contingent-AI™, to merge clinical and experimental data through machine learning. This approach addresses bias in data processing, enabling enhanced precision in drug development.

Strategically partnered with healthcare giants like Northwell Health, Janssen, Sema4, and Mt. Sinai, BioSymetrics has proven its capability to accelerate the discovery of precision medicines. As a remote-first company with key clusters in Toronto and Boston, they are actively expanding their team.

Since their Seed Round investment in 2017 by AJI Capital, they have continued to build momentum in life sciences and AI. BioSymetrics stands out for its integrated in silico and in vivo methodologies, aiming for faster, more accurate predictive results in drug discovery.